Immunotherapy with Mycobacterium vaccae and peripheral blood flow in long-treated leprosy patients, a randomised, placebo-controlled trial

European Journal of Vascular and Endovascular Surgery

Volumn 24, Issue 3, 2002, Pages 202-208

  Abbot, N C ^a   Beck, J S ^a   Feval, F ^b   Weiss, F ^b   Mobayen, M H ^b   Ghazi Saidi, K ^c   Dowlati, Y ^d   Velayati, A A ^e   Stanford, J L ^f  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Baba Baghi Leprosy Centre   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Blood flow; Chronic leprosy; Immunotherapy; Mycobacterium vaccae; Placebo controlled; Randomised clinical trial

Indexed keywords

PLACEBO; PROBIOTIC AGENT; TUBERCULIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER FLOWMETER; DOUBLE BLIND PROCEDURE; FINGER; HEAT SENSATION; HUMAN; IMMUNOTHERAPY; LEPROSY; LONG TERM CARE; MAJOR CLINICAL STUDY; MYCOBACTERIUM VACCAE; NOCICEPTION; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY EVALUATION; SKIN SENSATION; SKIN TEMPERATURE; SKIN TEST; TOUCH; VASOMOTOR REFLEX; ADOLESCENT; BLOOD FLOW; CHRONIC DISEASE; FEMALE; IMMUNOLOGY; LASER DOPPLER FLOWMETRY; MALE; MIDDLE AGED; MYCOBACTERIUM; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FINGERS; HUMANS; IMMUNOTHERAPY; LASER-DOPPLER FLOWMETRY; LEPROSY; MALE; MIDDLE AGED; MYCOBACTERIUM; REGIONAL BLOOD FLOW; TIME FACTORS;

EID: 0036718544     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1716     Document Type: Article

References (44)

1. STANFORD JL, TERENCIO DE LAS AGUAS J, TORRES P, GERVASIONI BO, RAVIOLI R. Studies on the effects of a potential immunotherapeutic agent in leprosy patients. Health Cooperation Papers 1987; 7: Proceedings of the Fourth European Leprosy Symposium: 201-206.
2. STANFORD JL, ROOK GAW, BAHR GM et al. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990; 8: 525-530.
3. YOUNG DB. Leprosy vaccines. In: Cryz SJ, ed. Vaccines and Immunotherapy. New York: Pergammon Press, 1991; 196-210.
4. RAMU G, GRANGE JM, STANFORD JL. Evaluation of adjunct immunotherapy with killed Mycobacterium vaccae in the treatment of multibacillary leprosy and erythema nodosum leprosum. In: Casal M, ed. Clinical Mycobacteriology. Barcelona: Prous Science, 1998; 393-402.
5. BERWANGER CS, INGLEDEW NB, SHUKLA N et al. Heat shock protein 65 increases arterial contractility which can be reversed with Mycobacterium vaccae. Proceedings of the International meeting on Heat Shock Proteins, Connecticut, 1998.
6. STANSBY G, CHAN YC, BERWANGER CS, SHUREY S, ROOK GAW, STANFORD JL. Prevention of experimental myointimal hyperplasia by immunomodulation. Eur J Vasc Endovasc Surg 2002; 23: 23-28.
7. BOTTASSO OA, INGLEDEW N, KENI M et al. Cellular immuno response to common mycobacterial antigensin subjects seropositive for Trypanosoma cruzi. Lancet 1994; 344: 1540-1541.
8. STANFORD JL, GRANGE JM. The meaning and structure of species as applied to mycobacteria. Tubercle 1974; 55: 143-152.
9. STANFORD JL, ROOK GAW. Taxonomic studies on the leprosy bacillus. Int J of Leprosy 1976; 44: 216-221.
10. STANFORD JL, STANFORD CA, ROOK GAW, GRANGE JM. Immunotherapy for tuberculosis-investigative and practical aspects. Clin Immunother 1994; 1: 430-440.
11. SHETTY VP, ANTIA NH. Nerve damage in leprosy. Int J Leprosy 1988; 56: 619-621.
12. ABBOT NC, BECK JS, BHASKAR RAO B et al. Circulation and sensation at the fingertips of claw hands. Leprosy Rev 1994; 65: 341-349.
13. BARNETSON J. Pathogenesis of bone changes in neural leprosy. Int J Leprosy 1951; 19: 297-300.
14. ABBOT NC, SWANSON BECK J, MOBAYEN MH, SAMSON PD, STANFORD JL. Reduced fingertip blood flow and peripheral dysautonomia in leprosy patients in Iranian Azerbaijan and in Maharashtra, India. Int J Leprosy 1993 61: 474-476.
15. ABBOT NC, SWANSON BECK J, SAMSON PD, BUTLIN CR, BENNETT PJ, GRANGE JM. Cold fingers in leprosy. Int J Leprosy 1993; 60: 580-586.
16. RAFI A-N. Molecular and immunological studies on "fully treated" long-term leprosy patients. PhD thesis, University of London; 1995.
17. GRANGE JM. New tuberculins (editorial) Lancet 1984; 1: 199-200.
18. STANFORD JL. Skin testing with mycobacterial reagents in leprosy. Tubercle 1984; 65: 63-74.
19. BONNER RF, NOSSAL R. Principles of laser Doppler flowmetry. In: Shepherd AP, Oberg O, eds. Laser Doppler Blood Flowmetry. Sweden: Kluwers, 1990; 17-45.
20. SEIFALIAN M, HOWELL K, STANSBY G, JACKSON AE, HAMILTON G, BLACK CM. Laser Doppler perfusion imaging: a new technique for measuring skin blood flow in rheumatology. Br J Rheumatol 1993; 32: 938.
21. SEIFALIAN M, STANSBY G, JACKSON AE, HOWELL K, HAMILTON G. Comparison of laser Doppler perfusion imaging, laser Doppler flowmetry and thermographic imaging for assessment of blood flow in human skin. Eur J Vasc Surg 1994; 8: 65-69.
22. PARISER KM, WOLFF SM. Pathophysiology of vasculitis. In: Loscalzo J, Creager MA, Dzau UJ, eds. Vascular Medicine - A Textbook of Vascular Biology and Diseases. Boston: Little, Brown and Co., 1992; 391-396.
23. BECK JS, ABBOT NC, SAMSON PD, BUTLIN CR, CREE IA. Impairment of vasomotor reflexes in the fingertips of leprosy patients. J Neurol Neurosurg Psychiatry 1991; 54: 965-971.
24. RIDLEY DS, JOPLING WH. Classification of leprosy according to immunity. A five group system. Int J Leprosy 1966; 34: 255-273.
25. PATERSON DE. Radiographic appearances and bone changes in leprosy - their cause, treatment, and practical application. In: Cochrane RG, McRobert Sir G, eds. Leprosy in Theory and Practice. Bristol: John Wright and Sons, 1959; 242-264.
26. PATERSON DE. Radiological bone changes and angiographic findings in leprosy: with special reference to the pathogenesis of "atrophic" conditions of the digits. J Fac Radio 1989; 6: 35-56.
27. CORUH G, MCDOUGALL AC. Untreated lepromatous leprosy-histological findings in cutaneous blood vessels. Int J Leprosy 1979; 47: 500-511.
28. YADAV SS. Arteriographic evaluation of vascular changes in leprosy. Angiology 1978; 29: 17-21.
29. 1q reactive immune complexes in patients with leprosy. Clin Experiment Immunol 1972; 12: 215-221.
30. XU Q, WILLEIT J, MAROSI M et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-259.
31. CHAN YC, SHUKLA N, ABDUS-SAMEE M et al. Anti heat shock protein 70 kDa antibodies in vascular patients. Eur J Vasc Endovasc Surg 1999; 18: 381-385.
32. STANFORD JL, THAPA N, RAFI AN, TORRES P, SINGH M. Anticuerpos frente a proteinas de estres en lepra de larga evolution, con su probable asociacion a deterioro tisular autoinmune y el resultado de aplicar inmunoterapia con Mycobacterium vaccae inactivado. Revista de Leprologia - Fontilles 1999; 22: 265-274.
33. DLUGOVITZKY D, BOTTASSO O, DOMININO JC et al. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir Med 1999; 93: 557-562.
34. JOHNSON JL, KAMYA RM, OKWERA A et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J Infect Dis 2000; 181: 1304-1312.
35. Luo Y. National Cooperation Group on Clinical Study of Mycobacterium vaccae Vaccine. The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis. Chi J Tubercul Respir Dis 2001; 24: 43-47.
36. HOPKIN JM. Mycobacterial immunization - agents to limit asthma. In: Hansel TT, Barnes PJ, eds. New Drugs for Asthma, Allergy and COPD. Vol. 31 Progress in Respiratory Research Basel, 2001, Karger.
37. CAMPOROTA L, CORKHILL A, LONG H et al. Effects of intradermal injection of SRL172 on allergen-induced airway responses and IL-5 generation by PBMC in asthma. Respir Crit Care Med 2000; 161, 3, Supp. 477.
38. ARKWRIGHT PD, DAVID TJ. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allerg Clin Immunol 2001; 107: 531-534.
39. LEHRER A, BRESSANELLI A, WACHSMANN V et al. Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol Med Microbiol 1998; 21: 71-7.
40. WADDELL RD, CHINTU C, LEIN AD et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis 2000; 30: S309-S315.
41. MARAVEYAS A, BABAN B, KENNARD D et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 1999; 10: 817-824.
42. HROUDA D, BABAN B, DUNSMUIR WD et al. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998; 82: 568-573.
43. ASSERSOHN L, SOUBERBIELLE BE, O'BRIEN ME et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin Oncol (R Coll Radiol) 2002; 14: 23-27.
44. ZUANY-AMORIM C, SAWICKA E, MANLIUS C et al. IL-10 and TGF-b mediated suppression of airway eosinophilia by allergen-specific regulatory CD4 + CD45Rblow T cells induced by SRP299 (killed Mycobacterium vaccae). Nature Med 2002 (in press).